ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

NetDania - New 12 months Low: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

22 Mar 2024 12:51:31 By NetDania Notify

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

18 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

26 Feb 2024 08:45:23 By NetDania Notify

Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference

26 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

23 Feb 2024 08:51:18 By NetDania Notify

Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update

07 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024

01 Feb 2024 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

24 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

16 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders

08 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Provides an Update on Rett Syndrome Program

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome

20 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease

19 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023

24 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety

22 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease

25 Oct 2023 07:00:00 By Nasdaq GlobeNewswire